Mylan Pays $465M to DOJ for EpiPen Rebates

Oct 10, 2016

Forbes

Mylan will pay $465 million to the Department of Justice to settle accusations the drugmaker improperly classified its EpiPen as a generic drug to avoid paying high rebates for branded treatments.

According to a Forbes article, Mylan said it reached a settlement with the DoJ, but the drugmaker will not have to admit wrongdoing. Mylan will pay a $465 million fine to “resolve questions that have been raised about the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector (collectively, “EpiPen Auto-Injector”) for purposes of the Medicaid Drug Rebate Program.”

Mylan has classified the drug as a non-innovator multiple source drug, according to CMS, causing Medicaid rebates to be just 13%, versus the 23% rebates it would have had to pay if EpiPen was treated as an innovator drug with little competition, the article said.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments